Pathways to Progress

The HIV Research for Prevention conference showcased advances with the potential to further decrease the rate of new infections.

More than two million people around the world are still infected with HIV each year. Given this stubbornly high rate of new infections, prevention remains a top priority. The limited number of early prevention methods have, over the years, mushroomed into a range of available or experimental preventative measures, including condoms, male circumcision, vaccines, microbicides, pre-exposure prophylaxis (PrEP), and behavioral modifications. October’s HIV Research for Prevention (HIVR4P) conference in Chicago took attendees on a whirlwind tour of the state of the art for many of these approaches. More than 1,400 leading scientists, advocates, and government officials discussed a number of potential vaccine strategies, microbicidal gels and rings, and different uses of antiretrovirals (ARVs) and antibodies for preventing HIV infection in the research and development pipeline. READ MORE »


Global HIV Vaccine Enterprise Appoints Interim Director

Gerald Voss, former head of GlaxoSmithKline (GSK) Vaccine’s HIV Vaccine program and vice president of the Enterprise’s Board of Directors, is now interim director of the Global HIV Vaccine Enterprise Secretariat, replacing longtime AIDS vaccine advocate William Snow, who has stepped down. Voss will oversee the Secretariat while the organization charts its future direction. After conducting a strategic review, the Enterprise will look for a new permanent director. Meanwhile, Snow will remain a senior advisor to the Secretariat and the Board of Directors. READ MORE »


VAX 0714 AntibodyGraphic

Antibodies: Protein Power! An illustration explaining the isolation of broadly neutralizing antibodies and how they are being used in HIV treatment, prevention, and cure research.

Special Features

AIDSVu Ribbon

Mapping AIDS in the US

AIDSVu is an interactive online tool illustrating the prevalence of HIV in the United States. Developed by the Rollins School of Public Health at Emory University in Atlanta three years ago, AIDSVu takes detailed data on persons living with an HIV infection diagnosis in the United States and presents it in a map. This year's updates, unveiled on HIV Testing Day June 27, includes maps showing HIV prevalence data for 20 cities by zip code or US Census tract. To view the map, go to

Learn the Basics

Understanding Ebola Vaccine Development

editorialWhat are the strategies scientists are using to develop vaccines to prevent Ebola?

Read more ...

Clinical Trials Database



An interactive search of trials and results



The Journal of AIDS Vaccine ResearchThe View from the Mothership

Global HIV Vaccine Enterprise Director William Snow reflects on the past and ponders the future course for the organization, and the field of HIV vaccine research overall.